Literature DB >> 24075462

The effect of the Cox-maze procedure for atrial fibrillation concomitant to mitral and tricuspid valve surgery.

Niv Ad1, Sari D Holmes, Paul S Massimiano, Graciela Pritchard, Lori E Stone, Linda Henry.   

Abstract

OBJECTIVES: Atrial fibrillation (AF) is associated with less favorable outcomes in patients undergoing mitral valve and tricuspid valve surgery. Despite growing evidence on the potential benefits of surgical ablation for AF there is significant variability among surgeons in treatment of AF. The purpose of our study was to assess the effect of the Cox-maze procedure on operative and follow-up outcomes.
METHODS: In our prospective study, patients who underwent isolated mitral valve or mitral valve+tricuspid valve surgery without history of AF (n = 506), with untreated AF (n = 75), or with Cox-maze procedure (n = 236) were included (N = 817). Sinus rhythm was captured according to Heart Rhythm Society guidelines. Patients who underwent the Cox-maze procedure were propensity score matched to patients without history of AF resulting in 208 pairs of patients.
RESULTS: Operative outcomes were comparable after propensity score matching (Cox-maze procedure vs no AF) stroke/transient ischemic attack (0.5% vs 0.5%; P = 1.00), renal failure (2.9% vs 1.4%; P = .34), and operative mortality (1.4% vs 1.4%; P = 1.00). High return to sinus rhythm was documented at 6, 12, and 24 months (92%, 91%, and 86%, respectively) as well as sinus rhythm off antiarrhythmic drugs (79%, 84%, and 82%, respectively). Incidence of embolic stroke in patients who underwent Cox-maze procedure was 1.7% (4 out of 232 patients) and 5.1 cases per 1000 person-years. No difference in 4-year cumulative survival between propensity score-matched groups (91.9% vs 86.9%; log rank, 1.67; P = .20), but higher for patients who underwent Cox-maze procedure versus patients with untreated AF (hazard ratio, 2.47; P = .048). Higher additive European System for Cardiac Operative Risk Evaluation (odds ratio, 1.40; P < .001) and limited surgeon experience with Cox-maze procedure (odds ratio, 3.60; P < .001) were significant predictors for failure to perform Cox-maze procedure.
CONCLUSIONS: In our center, 76% of patients undergoing mitral valve or mitral valve+tricuspid valve surgery experiencing AF underwent concomitant Cox-maze procedure, which is considerably higher than the national average. No increased morbidity was associated with the Cox-maze procedure with the benefit of very low thromboembolic rate. These results suggest the need for performance-based education for AF surgical ablation to achieve optimal outcomes.
Copyright © 2013 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  35.4; EuroSCORE; Eurpean System for Cardiac Operative Risk Evaluation; HRQL; MV; NSR; PSM; TV; health-related quality of life; mitral valve; normal sinus rhythm; propensity score matching; tricuspid valve

Mesh:

Year:  2013        PMID: 24075462     DOI: 10.1016/j.jtcvs.2013.08.013

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  11 in total

1.  Surgical ablation for atrial fibrillation: an editorial.

Authors:  Pouya Nezafati; Mojgan Gharipour; Mohammad Hassan Nezafati
Journal:  J Thorac Dis       Date:  2015-08       Impact factor: 2.895

2.  Maze permutations during minimally invasive mitral valve surgery.

Authors:  Anson M Lee
Journal:  Ann Cardiothorac Surg       Date:  2015-09

3.  Surgical management of atrial fibrillation at the time of septal myectomy.

Authors:  Eduard Quintana; James L Cox
Journal:  Ann Cardiothorac Surg       Date:  2017-07

4.  Late outcomes after the Cox maze IV procedure for atrial fibrillation.

Authors:  Matthew C Henn; Timothy S Lancaster; Jacob R Miller; Laurie A Sinn; Richard B Schuessler; Marc R Moon; Spencer J Melby; Hersh S Maniar; Ralph J Damiano
Journal:  J Thorac Cardiovasc Surg       Date:  2015-08-08       Impact factor: 5.209

5.  Effectiveness of Surgical Ablation in Patients With Atrial Fibrillation and Aortic Valve Disease.

Authors:  Matthew C Henn; Christopher P Lawrance; Laurie A Sinn; Jacob R Miller; Richard B Schuessler; Marc R Moon; Spencer J Melby; Hersh S Maniar; Ralph J Damiano
Journal:  Ann Thorac Surg       Date:  2015-07-22       Impact factor: 4.330

6.  Right minithoracotomy versus conventional median sternotomy for patients undergoing mitral valve surgery and Cox-maze IV ablation with entirely bipolar radiofrequency clamp.

Authors:  Zhaolei Jiang; Min Tang; Nan Ma; Hao Liu; Fangbao Ding; Chunrong Bao; Ju Mei
Journal:  Heart Vessels       Date:  2018-02-02       Impact factor: 2.037

7.  Performance of the Cox-maze IV procedure is associated with improved long-term survival in patients with atrial fibrillation undergoing cardiac surgery.

Authors:  Farah N Musharbash; Matthew R Schill; Laurie A Sinn; Richard B Schuessler; Hersh S Maniar; Marc R Moon; Spencer J Melby; Ralph J Damiano
Journal:  J Thorac Cardiovasc Surg       Date:  2017-09-27       Impact factor: 5.209

8.  Sinus Rhythm Restoration after Radiofrequency Ablation Improves Survival in Patients Undergoing Mitral Valve Surgery : A Eight Year Single Center Study.

Authors:  Carlo Rostagno; Irene Capecchi; Sandro Gelsomino; Enrico Carone; Pier Luigi Stefàno
Journal:  J Atr Fibrillation       Date:  2017-06-30

9.  Concomitant surgical ablation for atrial fibrillation is associated with increased risk of acute kidney injury but improved late survival.

Authors:  Nadia H Bakir; Ali J Khiabani; Robert M MacGregor; Meghan O Kelly; Laurie A Sinn; Richard B Schuessler; Hersh S Maniar; Spencer J Melby; Mohammad A Helwani; Ralph J Damiano
Journal:  J Thorac Cardiovasc Surg       Date:  2021-01-23       Impact factor: 6.439

10.  Comparison of two radiofrequency ablation devices for atrial fibrillation concomitant with a rheumatic valve procedure.

Authors:  Qin Jiang; Sheng-Zhong Liu; Lu Jiang; Ke-Li Huang; Jing Guo; Sheng-Shou Hu
Journal:  Chin Med J (Engl)       Date:  2019-06-20       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.